Four Cypriot companies’ ESG efforts acknowledged in Deloitte list

Four Cyprus-based companies made it to the in the Impact Category of the Deloitte Technology Fast 50 programme for Cyprus and the Middle East, which recognises companies that have an Environmental, Social, and Governance (ESG) element at the heart of their mission.

The four Cypriot companies – of nine in total – on Deloitte’s impact category list, are:

Irerobot: “The company’s proprietary technology, protocol, and algorithms are the foundations for developing, designing, and building a wide spectrum of interfaces, wearables, and other devices that enable sensory-enhanced experiences. Currently, Irerobot’s flagship project is ACETT, which stands for auditory communication enhancement through touch, and is set to revolutionise the tactile interface industry by enabling natural immersion in the acoustic world through the sense of touch.” _ Deloitte

Promed Bioscience: “Promed Bioscience was founded by a multidisciplinary team of scientists and entrepreneurs and is a biotech company that produces collagen-based biomaterials, including highly purified medical-grade atelocollagen, to address emergent needs in the research and medical fields. Promed Bioscience aims to provide science-based solutions as the aging of the population presents new challenges to health and wellbeing by developing high quality collagen products from animal tissue and distributing them internationally for a wide range of research, clinical and cosmeceutical applications.”

RSL Revolutionary Labs: “RSL Revolutionary Labs, is a healthcare-focused biotech company, offering unique skincare formulations designed in collaboration with scientists, dermatologists and oncology specialists and validated through vigorous R&D and clinical data, to address emergent needs in oncology patients. RSL provides unique natural products with the addition of novel molecularly engineered medical grade biomaterials specially formulated to alleviate skin irritation and promote wound and burn healing in cancer-associated skin conditions.”

Theramir: “Theramir, brings together a team of research entrepreneurs with significant experience in the discovery, development and commercialisation of innovative cancer therapeutics. The company develops novel microRNA-based therapeutics and companion diagnostics for patients and healthcare providers. Theramir’s precision oncology drug candidates offer significant advantages in terms of tumour selectivity and efficacy compared to current treatments and can provide a new avenue to successfully treat a wide range of cancers as part of a personalised medicine approach. Together with its investors and network of partners, the team is committed to exploiting the full potential of Theramir’s proprietary technologies, through its R&D efforts and by securing commercial partnerships and licensing agreements with biopharmaceutical partners that are expected to add substantial value to the company.”

For Deloitte’s full report, click here